Dr. Powles on Durvalumab in Urothelial Cancer

Video

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Thomas Powles, MD, Barts Cancer Institute, discusses durvalumab as a second-line therapy in locally advanced and metastatic urothelial cancer.

Durvalumab, is a selective, high-affinity human IgG1 monoclonal antibody that binds to both PD-1 and CD80.

In a phase Ib trial, durvalumab was associated with long-term durable responses in patients with metastatic bladder cancer patients who have previously failed on chemotherapy. The response rate was between 20% and 30% and there was also responses reported in the PD-L1—negative population.

According to Powles, durvalumab, along with agents like pembrolizumab (Keytruda), have superseded chemotherapy in the second-line.

Related Videos
Wenxin (Vincent) Xu, MD,
Wenxin (Vincent) Xu, MD
A panel of 4 experts on bladder cancer
A panel of 4 experts on bladder cancer
Wenxin (Vincent) Xu, MD
Patrick I. Borgen, MD
A panel of 5 experts on renal cell carcinoma
A panel of 5 experts on renal cell carcinoma
Kari Hacker, MD, PhD, NYU Grossman School of Medicine
Janos L. Tanyi, MD, PhD, associate professor, Obstetrics and Gynecology, Hospital of the University of Pennsylvania